Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
LEO Pharma's Patient-Centric Approach
August 8th 2024In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is LEO Pharma positioning itself to capitalize on the unmet needs, patient centric initiatives, and more.
Informing Organon’s Strategic Approach From an OB-GYN POV
August 2nd 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses how she's using her in-practice experience as an OB-GYN to inform Organon's strategic approach to addressing maternal health challenges.
Addressing Maternal Health Disparities and Driving Change
August 1st 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, identifies Organon's efforts to invest in research, education, and its pipeline to focus on critical areas of need in maternal health.
Critical Changes Needed to Close Gaps in R&D for Maternal Health Solutions
July 31st 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, talks about the most critical to close the gaps in R&D for maternal health solutions and how feasible the fixes are.
The Broader Societal Implications of Maternal Health Issues
July 30th 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses the societal implications of maternal health issues both short and long term.
Addressing OUD Treatment Gaps & Improving Patient Outcomes
July 23rd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.
Braeburn on BRIXADI® Research and Addressing Fentanyl's Impact on OUD
July 22nd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.